Welcome to NGC. Skip directly to: Search Box, Navigation, Content.


Brief Summary

GUIDELINE TITLE

Entecavir for the treatment of chronic hepatitis B.

BIBLIOGRAPHIC SOURCE(S)

  • National Institute for Health and Clinical Excellence (NICE). Entecavir for the treatment of chronic hepatitis B. London (UK): National Institute for Health and Clinical Excellence (NICE); 2008 Aug. 25 p. (Technology appraisal guidance; no. 153).

GUIDELINE STATUS

This is the current release of the guideline.

BRIEF SUMMARY CONTENT

 
RECOMMENDATIONS
 EVIDENCE SUPPORTING THE RECOMMENDATIONS
 IDENTIFYING INFORMATION AND AVAILABILITY
 DISCLAIMER

 Go to the Complete Summary

RECOMMENDATIONS

MAJOR RECOMMENDATIONS

This guidance does not apply to people with chronic hepatitis B who also have hepatitis C, hepatitis D or human immunodeficiency virus (HIV).

Entecavir, within its marketing authorisation, is recommended as an option for the treatment of people with chronic hepatitis B e antigen (HBeAg)-positive or HBeAg-negative hepatitis B in whom antiviral treatment is indicated.

CLINICAL ALGORITHM(S)

None provided

EVIDENCE SUPPORTING THE RECOMMENDATIONS

TYPE OF EVIDENCE SUPPORTING THE RECOMMENDATIONS

The type of evidence supporting the recommendations is not specifically stated.

IDENTIFYING INFORMATION AND AVAILABILITY

BIBLIOGRAPHIC SOURCE(S)

  • National Institute for Health and Clinical Excellence (NICE). Entecavir for the treatment of chronic hepatitis B. London (UK): National Institute for Health and Clinical Excellence (NICE); 2008 Aug. 25 p. (Technology appraisal guidance; no. 153).

ADAPTATION

Not applicable: The guideline was not adapted from another source.

DATE RELEASED

2008 Aug

GUIDELINE DEVELOPER(S)

National Institute for Health and Clinical Excellence (NICE) - National Government Agency [Non-U.S.]

SOURCE(S) OF FUNDING

National Institute for Health and Clinical Excellence (NICE)

GUIDELINE COMMITTEE

Appraisal Committee

COMPOSITION OF GROUP THAT AUTHORED THE GUIDELINE

Committee Members: Professor David Barnett, Professor of Clinical Pharmacology, University of Leicester; Dr David W Black, Director of Public Health, Derbyshire County PCT; Dr Carol Campbell, Senior Lecturer, University of Teesside; Dr Peter Clarke, Consultant Medical Oncologist, Clatterbridge Centre for Oncology; Dr Christine Davey, Senior Researcher, North Yorkshire Alliance R & D Unit; Dr Mike Davies, Consultant Physician, Manchester Royal Infirmary; Dr Dyfrig Hughes, Reader in Pharmacoeconomics, Centre for the Economics of Health and Policy in Health, Bangor University; Dr Catherine Jackson, Clinical Lecturer in Primary Care Medicine, Alyth Health Centre; Dr Peter Jackson, Clinical Pharmacologist, Sheffield Teaching Hospitals NHS Foundation Trust; Professor Peter Jones, Pro Vice Chancellor for Research & Enterprise, Keele University; Ms Rachel Lewis, Practice Development Facilitator, Manchester PCT; Professor Jonathan Michaels, Professor of Vascular Surgery, University of Sheffield; Dr Eugene Milne, Deputy Medical Director, North East Strategic Health Authority; Dr Simon Mitchell, Consultant Neonatal Paediatrician, St Mary's Hospital, Manchester; Dr Richard Alexander Nakielny, Consultant Radiologist, Royal Hallamshire Hospital, Sheffield; Dr Katherine Payne, Health Economics Research Fellow, University of Manchester; Dr Philip Rutledge, GP and Consultant in Medicines Management, NHS Lothian; Mr Miles Scott, Chief Executive, Bradford Teaching Hospitals NHS Foundation Trust; Dr Surinder Sethi, Consultant in Public Health Medicine, North West Specialised Services Commissioning Team; Professor Andrew Stevens, Chair of Appraisal Committee C; Mr William Turner, Consultant Urologist, Addenbrookes Hospital

FINANCIAL DISCLOSURES/CONFLICTS OF INTEREST

Committee members are asked to declare any interests in the technology to be appraised. If it is considered there is a conflict of interest, the member is excluded from participating further in that appraisal.

GUIDELINE STATUS

This is the current release of the guideline.

GUIDELINE AVAILABILITY

AVAILABILITY OF COMPANION DOCUMENTS

The following are available:

  • Entecavir for the treatment of chronic hepatitis B. Quick reference guide. London (UK): National Institute for Health and Clinical Excellence (NICE); 2008 Aug. 2 p. (Technology appraisal 153). Available in Portable Document Format (PDF) from the National Institute for Health and Clinical Excellence (NICE) Web site.
  • Entecavir for the treatment of chronic hepatitis B. Costing statement. London (UK): National Institute for Health and Clinical Excellence (NICE); 2008 Aug. 2 p. (Technology appraisal 153). Available in Portable Document Format (PDF) from the NICE Web site.
  • Entecavir for the treatment of chronic hepatitis B. Audit support. London (UK): National Institute for Health and Clinical Excellence (NICE); 2008. 4 p. (Technology appraisal 153). Available in Portable Document Format (PDF) from the NICE Web site.
  • Entecavir for the treatment of chronic hepatitis B. Evidence Review Group report. Southampton Health Technology Assessments Centre (SHTAC); 2008 Feb. 120 p. (Technology appraisal 153). Available in Portable Document Format (PDF) from the NICE Web site.

Print copies: Available from the National Health Service (NHS) Response Line 0870 1555 455. ref: N1660. 11 Strand, London, WC2N 5HR

PATIENT RESOURCES

The following is available:

Print copies: Available from the NHS Response Line 0870 1555 455. ref: N1661. 11 Strand, London, WC2N 5HR.

Please note: This patient information is intended to provide health professionals with information to share with their patients to help them better understand their health and their diagnosed disorders. By providing access to this patient information, it is not the intention of NGC to provide specific medical advice for particular patients. Rather we urge patients and their representatives to review this material and then to consult with a licensed health professional for evaluation of treatment options suitable for them as well as for diagnosis and answers to their personal medical questions. This patient information has been derived and prepared from a guideline for health care professionals included on NGC by the authors or publishers of that original guideline. The patient information is not reviewed by NGC to establish whether or not it accurately reflects the original guideline's content.

NGC STATUS

COPYRIGHT STATEMENT

This NGC summary is based on the original guideline, which is subject to the guideline developer's copyright restrictions.

DISCLAIMER

NGC DISCLAIMER

The National Guideline Clearinghouse™ (NGC) does not develop, produce, approve, or endorse the guidelines represented on this site.

All guidelines summarized by NGC and hosted on our site are produced under the auspices of medical specialty societies, relevant professional associations, public or private organizations, other government agencies, health care organizations or plans, and similar entities.

Guidelines represented on the NGC Web site are submitted by guideline developers, and are screened solely to determine that they meet the NGC Inclusion Criteria which may be found at http://www.guideline.gov/about/inclusion.aspx .

NGC, AHRQ, and its contractor ECRI Institute make no warranties concerning the content or clinical efficacy or effectiveness of the clinical practice guidelines and related materials represented on this site. Moreover, the views and opinions of developers or authors of guidelines represented on this site do not necessarily state or reflect those of NGC, AHRQ, or its contractor ECRI Institute, and inclusion or hosting of guidelines in NGC may not be used for advertising or commercial endorsement purposes.

Readers with questions regarding guideline content are directed to contact the guideline developer.


 

 

   
DHHS Logo